OncoZenge announces European patent for BupiZenge lozenge

By DrBicuspid Staff

January 8, 2021 -- Moberg Pharma subsidiary OncoZenge announced that the European Patent Office has granted the firm patent No. 3,284,459, which protects its BupiZenge lozenge.

The sustained-release lozenge containing bupivacaine is currently being developed for the treatment of pain due to oral mucositis. The patent is in effect until 2032 and is a divisional of the previously granted European patent No. 2,701,681. The previous patent specifically protects the use of lozenges for the treatment of pain due to oral mucositis for cancer patients.

BupiZenge already has similar patents in the U.S. and Canada, OncoZenge said.


Copyright © 2021 DrBicuspid.com
 

To read this and get access to all of the exclusive content on DrBicuspid.com create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a DrBicuspid.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: